Fig. 4
EVPs contribute to lymphatic vascular beds but do not originate from lymphatics. a, b Representative micrographs of tumor sections taken from Cdh5-CreER RosaYFP and Sox18-CreER RosaYFP lineage tracing models. At day 15 YFP+ vessels co-localized with lymphatic marker Lyve1 (white arrow) and Podoplanin (PDPN). Green arrows represent Lyve1+ vessels that are not YFP+ (n = 5). c Schematic diagram of the Prox1-CreER tdTomato lineage tracing model employed with B16-F0 melanoma cells injected at day 0 (D0), with mice receiving tamoxifen (Tam) 3-days post tumor inoculation (n = 5). d Lyve1+PDPN+ vessels co-localized with Tomato+ (Prox1) vessels. e Flow cytometry plots demonstrating that Prox1+CD34+LIN- cells do not contribute to the endothelial hierarchy. Results presented as mean ± SEM. Scale bar represents 150 μm. EVP endovascular progenitor, TA transit amplifying, D definitive differentiated
